You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Mechanisms for Delaying/Preventing Type 1 Diabetes Clinical Onset

  • Authors: Alberto Pugliese, MD; Colin Dayan, MA, FRCP, PhD; Mark A. Atkinson, PhD
  • CME / ABIM MOC Released: 5/24/2023
  • Valid for credit through: 5/24/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for pediatric endocrinologists, diabetologists/endocrinologists, pediatricians, primary care physicians, and other clinicians who care for patients with or at risk for T1D.

The goal of this activity is for learners to be better able to describe how anti-CD3 monoclonal antibodies can delay/prevent clinical T1D in patients at risk of developing the disease.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of action for new treatment strategies for T1D
    • Clinical trial data for new treatment strategies for T1D


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


  • Alberto Pugliese, MD

    The Samuel Rahbar Endowed Chair in Diabetes & Drug Discovery
    Chair and Professor, Department of Diabetes Immunology
    Director, The Wanek Family Project for Type 1 Diabetes
    Arthur Riggs Diabetes & Metabolism Research Institute
    City of Hope
    Duarte, California, United States


    Alberto Pugliese, MD, has the following relevant financial relationships:
    Consultant or advisor for: Quell Therapeutics (former); Provention Bio, Inc. (former)

  • Colin Dayan, MA, FRCP, PhD

    Professor of Clinical Diabetes and Metabolism
    Director of the Joint Research Office
    Cardiff & Vale Health Board and Cardiff University
    Senior Clinical Researcher
    Wellcome Centre for Human Genetics
    University of Oxford
    Oxford, England


    Colin Dayan, MA, FRCP, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Avotres Inc.; Janssen; Eli Lilly and Company; Midatech Pharma PLC; Merck Sharp & Dohme GmbH; Novartis; Novo Nordisk; Provention Bio; Sanofi Genzyme; SERVIER; UCB Pharma, Inc.; Viela Bio; Worg Pharmaceuticals
    Research funding from: Provention Bio
    Patent beneficiary of: Midatech Pharma PLC, a patent for gold nanoparticles conjugated with proinsulin for type 1 diabetes

  • Mark A. Atkinson, PhD

    American Diabetes Association Eminent Scholar for Diabetes Research
    Jeffrey Keene Family Professor
    Director, UF Diabetes Institute
    Departments of Pathology and Pediatrics
    The University of Florida
    Gainesville, Florida, United States


    Mark A. Atkinson, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Diamyd Medical; Endsulin
    Stock options from: Endsulin; Miromatrix Medical Inc.
    Owns stock (publicly traded) in: Diamyd Medical
    Monetary compensation for an executive role from: Diamyd Medical as board member


  • Anne G. Le, PharmD

    Senior Medical Education Director, Medscape, LLC


    Anne G. Le, PharmD, has no relevant financial relationships.

  • Frederick Stange, DO

    Scientific Content Manager, Medscape, LLC


    Frederick Stange, DO, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Mechanisms for Delaying/Preventing Type 1 Diabetes Clinical Onset




Educational Impact Challenge

What did you learn from this activity? Please click on the "Next" button to proceed to a brief survey to see how your knowledge improved after the education. You can also see how your answers compare with those of your peers.

  • Print